Clearside Biomedical (CLSD) Competitors

Clearside Biomedical (NASDAQ:CLSD) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.

Which has more risk and volatility, CLSD or SLRN?

Clearside Biomedical has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Do analysts recommend CLSD or SLRN?

Clearside Biomedical presently has a consensus price target of $4.80, indicating a potential upside of 493.99%. Acelyrin has a consensus price target of $9.60, indicating a potential upside of 322.91%. Given Clearside Biomedical's stronger consensus rating and higher probable upside, analysts clearly believe Clearside Biomedical is more favorable than Acelyrin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearside Biomedical	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Acelyrin	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Do institutionals and insiders hold more shares of CLSD or SLRN?

18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 6.2% of Clearside Biomedical shares are owned by insiders. Comparatively, 13.6% of Acelyrin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media refer more to CLSD or SLRN?

In the previous week, Clearside Biomedical had 3 more articles in the media than Acelyrin. MarketBeat recorded 3 mentions for Clearside Biomedical and 0 mentions for Acelyrin. Clearside Biomedical's average media sentiment score of 1.40 beat Acelyrin's score of 0.00 indicating that Clearside Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Clearside Biomedical	Positive
Acelyrin	Neutral

Is CLSD or SLRN more profitable?

Acelyrin has a net margin of 0.00% compared to Clearside Biomedical's net margin of -413.83%. Clearside Biomedical's return on equity of 0.00% beat Acelyrin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearside Biomedical	-413.83%	N/A	-92.90%
Acelyrin	N/A	-44.12%	-39.02%

Does the MarketBeat Community prefer CLSD or SLRN?

Clearside Biomedical received 361 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 67.32% of users gave Clearside Biomedical an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.

Company	Underperform	Outperform
Clearside Biomedical	Outperform Votes 377 67.32%	Underperform Votes 183 32.68%
Acelyrin	Outperform Votes 16 55.17%	Underperform Votes 13 44.83%

Which has higher earnings and valuation, CLSD or SLRN?

Clearside Biomedical has higher revenue and earnings than Acelyrin. Clearside Biomedical is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearside Biomedical	$3.76M	16.68	-$32.49M	-$0.41	-1.97
Acelyrin	N/A	N/A	-$381.64M	-$2.69	-0.84

Summary

Clearside Biomedical beats Acelyrin on 12 of the 17 factors compared between the two stocks.